PMID- 34518091
OWN - NLM
STAT- MEDLINE
DCOM- 20211122
LR  - 20211122
IS  - 1590-3729 (Electronic)
IS  - 0939-4753 (Linking)
VI  - 31
IP  - 11
DP  - 2021 Oct 28
TI  - Effects of GLP-1 receptor agonists on myokine levels and pro-inflammatory 
      cytokines in patients with type 2 diabetes mellitus.
PG  - 3193-3201
LID - S0939-4753(21)00336-7 [pii]
LID - 10.1016/j.numecd.2021.07.015 [doi]
AB  - BACKGROUND AND AIMS: To evaluate the change in circulating serum irisin and 
      interleukin-6 (IL-6), in patients with type 2 diabetes mellitus (T2DM) after 6 
      and 12 months of GLP-1 treatment. METHODS AND RESULTS: Eighty-five patients with 
      T2DM inadequately controlled with insulin or other hypoglycaemic drugs were added 
      to dulaglutide (N degrees  = 44) and liraglutide (N degrees  = 41) treatment. After 6 months of 
      GLP-1 analogues a significant decrease in BMI (p < 0.001), waist circumference 
      (WC) (p < 0.001), fasting blood glucose (p < 0.001), HbA1c (p < 0.001), total 
      cholesterol (p < 0.001), LDL-cholesterol (p = 0.003), triglycerides (p = 0.017), 
      IL-6 (p = 0.045) and a significant increase in serum irisin (p < 0.001) were 
      observed compared to baseline. After 12 months of treatment no significant 
      differences were found compared to the levels at 6 months. The change in irisin 
      from baseline (Delta_irisin) was significantly related to the changes in 
      total-cholesterol (Delta_total-cholesterol) (r = -0.293; p = 0.020), while the change 
      in IL-6 (Delta_IL-6) was significantly related to the changes in WC (Delta_WC) 
      (r = 0.347; p = 0.006). CONCLUSIONS: Additive treatment with GLP1-analogues 
      results in an increase in serum circulating irisin levels and a decrease in IL-6. 
      The post-treatment change in irisin was correlated with a decrease in total 
      cholesterol, while the change in IL-6 was correlated with a decrease in WC.
CI  - Copyright (c) 2021 The Italian Diabetes Society, the Italian Society for the Study 
      of Atherosclerosis, the Italian Society of Human Nutrition and the Department of 
      Clinical Medicine and Surgery, Federico II University. Published by Elsevier B.V. 
      All rights reserved.
FAU - Guarnotta, Valentina
AU  - Guarnotta V
AD  - Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e 
      Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Sezione di Malattie 
      Endocrine, del Ricambio e della Nutrizione, Universita di Palermo, Italy.
FAU - Bianco, Maria J
AU  - Bianco MJ
AD  - Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e 
      Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Sezione di Malattie 
      Endocrine, del Ricambio e della Nutrizione, Universita di Palermo, Italy.
FAU - Vigneri, Enrica
AU  - Vigneri E
AD  - Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e 
      Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Sezione di Malattie 
      Endocrine, del Ricambio e della Nutrizione, Universita di Palermo, Italy.
FAU - Panto', Felicia
AU  - Panto' F
AD  - Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e 
      Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Sezione di Malattie 
      Endocrine, del Ricambio e della Nutrizione, Universita di Palermo, Italy.
FAU - Lo Sasso, Bruna
AU  - Lo Sasso B
AD  - Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory 
      Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, 
      University of Palermo, Palermo, Italy; Dipartimento di Medicina di laboratorio, 
      AOUP "P. Giaccone", Palermo, Italy.
FAU - Ciaccio, Marcello
AU  - Ciaccio M
AD  - Institute of Clinical Biochemistry, Clinical Molecular Medicine and Laboratory 
      Medicine, Department of Biomedicine, Neurosciences and Advanced Diagnostics, 
      University of Palermo, Palermo, Italy; Dipartimento di Medicina di laboratorio, 
      AOUP "P. Giaccone", Palermo, Italy.
FAU - Pizzolanti, Giuseppe
AU  - Pizzolanti G
AD  - Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e 
      Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Sezione di Malattie 
      Endocrine, del Ricambio e della Nutrizione, Universita di Palermo, Italy. 
      Electronic address: giuseppe.pizzolanti@unipa.it.
FAU - Giordano, Carla
AU  - Giordano C
AD  - Dipartimento di Promozione della Salute, Materno-Infantile, Medicina Interna e 
      Specialistica di Eccellenza "G. D'Alessandro" (PROMISE), Sezione di Malattie 
      Endocrine, del Ricambio e della Nutrizione, Universita di Palermo, Italy. 
      Electronic address: carla.giordano@unipa.it.
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20210724
PL  - Netherlands
TA  - Nutr Metab Cardiovasc Dis
JT  - Nutrition, metabolism, and cardiovascular diseases : NMCD
JID - 9111474
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (FNDC5 protein, human)
RN  - 0 (Fibronectins)
RN  - 0 (GLP1R protein, human)
RN  - 0 (Glucagon-Like Peptide-1 Receptor)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (IL6 protein, human)
RN  - 0 (Immunoglobulin Fc Fragments)
RN  - 0 (Incretins)
RN  - 0 (Inflammation Mediators)
RN  - 0 (Insulin)
RN  - 0 (Interleukin-6)
RN  - 0 (Recombinant Fusion Proteins)
RN  - 62340-29-8 (Glucagon-Like Peptides)
RN  - 839I73S42A (Liraglutide)
RN  - 97C5T2UQ7J (Cholesterol)
RN  - WTT295HSY5 (dulaglutide)
SB  - IM
MH  - Aged
MH  - Biomarkers/blood
MH  - Blood Glucose/*drug effects/metabolism
MH  - Cholesterol/blood
MH  - Diabetes Mellitus, Type 2/blood/diagnosis/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Fibronectins/*blood
MH  - Glucagon-Like Peptide-1 Receptor/*agonists
MH  - Glucagon-Like Peptides/adverse effects/*analogs & derivatives/therapeutic use
MH  - Humans
MH  - Hypoglycemic Agents/adverse effects/*therapeutic use
MH  - Immunoglobulin Fc Fragments/adverse effects/*therapeutic use
MH  - Incretins/adverse effects/*therapeutic use
MH  - Inflammation Mediators/blood
MH  - Insulin/therapeutic use
MH  - Interleukin-6/*blood
MH  - Liraglutide/adverse effects/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Recombinant Fusion Proteins/adverse effects/*therapeutic use
MH  - Time Factors
MH  - Treatment Outcome
MH  - Waist Circumference
OTO - NOTNLM
OT  - Adipokines
OT  - Dulaglutide
OT  - Interleukin-6
OT  - Irisin
OT  - Liraglutide
COIS- Declaration of competing interest Authors have nothing to disclose.
EDAT- 2021/09/15 06:00
MHDA- 2021/11/23 06:00
CRDT- 2021/09/14 05:51
PHST- 2021/02/16 00:00 [received]
PHST- 2021/05/17 00:00 [revised]
PHST- 2021/07/16 00:00 [accepted]
PHST- 2021/09/15 06:00 [pubmed]
PHST- 2021/11/23 06:00 [medline]
PHST- 2021/09/14 05:51 [entrez]
AID - S0939-4753(21)00336-7 [pii]
AID - 10.1016/j.numecd.2021.07.015 [doi]
PST - ppublish
SO  - Nutr Metab Cardiovasc Dis. 2021 Oct 28;31(11):3193-3201. doi: 
      10.1016/j.numecd.2021.07.015. Epub 2021 Jul 24.